Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Altered cell-cycle control, inflammation and adhesion in high-risk persistent bronchial dysplasia.

Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, Friedman MB, Dwyer-Nield LD, Tennis MA, O'Keefe MC, Donald EJ, Malloy JM, van Bokhoven A, Wilson S, Koch PJ, O'Shea C, Coldren C, Orlicky DJ, Lu X, Baron AE, Hickey G, Kennedy TC, Powell R, Heasley L, Bunn PA, Geraci M, Nemenoff RA.

Cancer Res. 2018 Jul 11. pii: canres.3822.2017. doi: 10.1158/0008-5472.CAN-17-3822. [Epub ahead of print]

PMID:
29997230
2.

Reply to Sohal: Airway Basal Cell Reprogramming and Epithelial-Mesenchymal Transition: A Potential Key to Understanding Early Chronic Obstructive Pulmonary Disease.

Ghosh M, Miller YE, Vandivier RW; all authors.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1645-1646. doi: 10.1164/rccm.201801-0103LE. No abstract available.

PMID:
29385351
3.

Exhaustion of Airway Basal Progenitor Cells in Early and Established Chronic Obstructive Pulmonary Disease.

Ghosh M, Miller YE, Nakachi I, Kwon JB, Barón AE, Brantley AE, Merrick DT, Franklin WA, Keith RL, Vandivier RW.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):885-896. doi: 10.1164/rccm.201704-0667OC.

PMID:
29211494
4.

Protection against vascular leak in neprilysin transgenic mice with complex overexpression pattern.

Wick MJ, Loomis ZL, Harral JW, Le M, Wehling CA, Miller YE, Dempsey EC.

Transgenic Res. 2016 Dec;25(6):773-784. Epub 2016 Jul 1.

PMID:
27369050
5.

Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma.

Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch FR, Heasley L, Bunn PA Jr, Franklin WA.

Cancer Prev Res (Phila). 2016 Jan;9(1):96-104. doi: 10.1158/1940-6207.CAPR-15-0305. Epub 2015 Nov 5.

6.

Validation of a multiprotein plasma classifier to identify benign lung nodules.

Vachani A, Pass HI, Rom WN, Midthun DE, Edell ES, Laviolette M, Li XJ, Fong PY, Hunsucker SW, Hayward C, Mazzone PJ, Madtes DK, Miller YE, Walker MG, Shi J, Kearney P, Fang KC, Massion PP.

J Thorac Oncol. 2015 Apr;10(4):629-37. doi: 10.1097/JTO.0000000000000447.

7.

Validation of a blood protein signature for non-small cell lung cancer.

Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, Pass HI, Rom WN, Muley T, Meister M, Franklin W, Miller YE, Brody EN, Ostroff RM.

Clin Proteomics. 2014 Aug 1;11(1):32. doi: 10.1186/1559-0275-11-32. eCollection 2014.

8.

Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions.

Nakachi I, Rice JL, Coldren CD, Edwards MG, Stearman RS, Glidewell SC, Varella-Garcia M, Franklin WA, Keith RL, Lewis MT, Gao B, Merrick DT, Miller YE, Geraci MW.

Cancer Prev Res (Phila). 2014 Feb;7(2):255-65. doi: 10.1158/1940-6207.CAPR-12-0485. Epub 2013 Dec 17.

9.

Lung cancer chemoprevention: current status and future prospects.

Keith RL, Miller YE.

Nat Rev Clin Oncol. 2013 Jun;10(6):334-43. doi: 10.1038/nrclinonc.2013.64. Epub 2013 May 21. Review.

10.

Neprilysin regulates pulmonary artery smooth muscle cell phenotype through a platelet-derived growth factor receptor-dependent mechanism.

Karoor V, Oka M, Walchak SJ, Hersh LB, Miller YE, Dempsey EC.

Hypertension. 2013 Apr;61(4):921-30. doi: 10.1161/HYPERTENSIONAHA.111.199588. Epub 2013 Feb 4.

11.

Sleep-disordered breathing, hypoxemia, and cancer mortality.

Miller YE, Karoor V, Dempsey EC, Fagan KA.

Am J Respir Crit Care Med. 2013 Feb 1;187(3):330-1. No abstract available.

PMID:
23378442
12.

Endobronchial miRNAs as biomarkers in lung cancer chemoprevention.

Mascaux C, Feser WJ, Lewis MT, Barón AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR.

Cancer Prev Res (Phila). 2013 Feb;6(2):100-8. doi: 10.1158/1940-6207.CAPR-12-0382. Epub 2012 Dec 26.

13.

Non-invasive breath analysis of pulmonary nodules.

Peled N, Hakim M, Bunn PA Jr, Miller YE, Kennedy TC, Mattei J, Mitchell JD, Hirsch FR, Haick H.

J Thorac Oncol. 2012 Oct;7(10):1528-33.

14.

Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism.

Karoor V, Le M, Merrick D, Fagan KA, Dempsey EC, Miller YE.

Cancer Prev Res (Phila). 2012 Aug;5(8):1061-71. doi: 10.1158/1940-6207.CAPR-12-0069-T. Epub 2012 Jun 14.

15.

Senescence in chronic obstructive pulmonary disease.

Tuder RM, Kern JA, Miller YE.

Proc Am Thorac Soc. 2012 May;9(2):62-3. doi: 10.1513/pats.201201-012MS. Review.

16.

Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study.

Egloff AM, Gaither Davis A, Shuai Y, Land S, Pilewski JM, Luketich JD, Landreneau R, Miller YE, Grandis JR, Siegfried JM.

Respir Res. 2012 Feb 1;13:9. doi: 10.1186/1465-9921-13-9.

17.

Progressive endobronchial premalignancy: marked by original CIN.

Coldren CD, Miller YE.

Am J Respir Crit Care Med. 2011 Oct 15;184(8):869-70. doi: 10.1164/rccm.201108-1476ED. No abstract available.

18.

Oral iloprost improves endobronchial dysplasia in former smokers.

Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, Franklin WA, Mao J, Wilson DO, Merrick DT, Hirsch FR, Kennedy TC, Bunn PA Jr, Geraci MW, Miller YE.

Cancer Prev Res (Phila). 2011 Jun;4(6):793-802. doi: 10.1158/1940-6207.CAPR-11-0057.

19.

Lung cancer diagnosis from proteomic analysis of preinvasive lesions.

Rahman SM, Gonzalez AL, Li M, Seeley EH, Zimmerman LJ, Zhang XJ, Manier ML, Olson SJ, Shah RN, Miller AN, Putnam JB, Miller YE, Franklin WA, Blot WJ, Carbone DP, Shyr Y, Caprioli RM, Massion PP.

Cancer Res. 2011 Apr 15;71(8):3009-17. doi: 10.1158/0008-5472.CAN-10-2510. Epub 2011 Apr 12.

20.

Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk.

Rafnar T, Sulem P, Besenbacher S, Gudbjartsson DF, Zanon C, Gudmundsson J, Stacey SN, Kostic JP, Thorgeirsson TE, Thorleifsson G, Bjarnason H, Skuladottir H, Gudbjartsson T, Isaksson HJ, Isla D, Murillo L, García-Prats MD, Panadero A, Aben KK, Vermeulen SH, van der Heijden HF, Feser WJ, Miller YE, Bunn PA, Kong A, Wolf HJ, Franklin WA, Mayordomo JI, Kiemeney LA, Jonsson S, Thorsteinsdottir U, Stefansson K.

Cancer Res. 2011 Feb 15;71(4):1356-61. doi: 10.1158/0008-5472.CAN-10-2852. Epub 2011 Feb 8.

21.

Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.

Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, Pass HI, Rom WN, Siegfried JM, Stewart A, Walker JJ, Weissfeld JL, Williams S, Zichi D, Brody EN.

PLoS One. 2010 Dec 7;5(12):e15003. doi: 10.1371/journal.pone.0015003.

22.

Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease.

Wick MJ, Buesing EJ, Wehling CA, Loomis ZL, Cool CD, Zamora MR, Miller YE, Colgan SP, Hersh LB, Voelkel NF, Dempsey EC.

Am J Respir Crit Care Med. 2011 Feb 1;183(3):330-40. doi: 10.1164/rccm.201002-0154OC. Epub 2010 Sep 2.

23.

Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.

Karoor V, Le M, Merrick D, Dempsey EC, Miller YE.

Cancer Prev Res (Phila). 2010 Sep;3(9):1141-7. doi: 10.1158/1940-6207.CAPR-10-0005. Epub 2010 Jul 20.

24.

Does unilateral DIPNECH provide clues to pathogenesis?

Miller YE.

J Thorac Oncol. 2010 Jun;5(6):761-2. doi: 10.1097/JTO.0b013e3181dd0ba7. No abstract available.

25.

The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence.

Varella-Garcia M, Schulte AP, Wolf HJ, Feser WJ, Zeng C, Braudrick S, Yin X, Hirsch FR, Kennedy TC, Keith RL, Barón AE, Belinsky SA, Miller YE, Byers T, Franklin WA.

Cancer Prev Res (Phila). 2010 Apr;3(4):447-53. doi: 10.1158/1940-6207.CAPR-09-0165. Epub 2010 Mar 23.

26.

Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.

Keith RL, Karoor V, Mozer AB, Hudish TM, Le M, Miller YE.

Lung Cancer. 2010 Oct;70(1):37-42. doi: 10.1016/j.lungcan.2010.01.004. Epub 2010 Jan 29.

27.

Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development.

Kim WY, Jin Q, Oh SH, Kim ES, Yang YJ, Lee DH, Feng L, Behrens C, Prudkin L, Miller YE, Lee JJ, Lippman SM, Hong WK, Wistuba II, Lee HY.

Cancer Res. 2009 Sep 15;69(18):7439-48. doi: 10.1158/0008-5472.CAN-08-3792. Epub 2009 Sep 8. Erratum in: Cancer Res. 2009 Oct 15;69(20):8216.

28.

Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer.

Massion PP, Zou Y, Uner H, Kiatsimkul P, Wolf HJ, Baron AE, Byers T, Jonsson S, Lam S, Hirsch FR, Miller YE, Franklin WA, Varella-Garcia M.

PLoS One. 2009 Jun 9;4(6):e5611. doi: 10.1371/journal.pone.0005611.

29.

A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer.

Kelly K, Kittelson J, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Hirsch FR, Bunn PA, Miller YE.

Cancer Prev Res (Phila). 2009 May;2(5):440-9. doi: 10.1158/1940-6207.CAPR-08-0136. Epub 2009 Apr 28.

30.

Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia.

Dempsey EC, Wick MJ, Karoor V, Barr EJ, Tallman DW, Wehling CA, Walchak SJ, Laudi S, Le M, Oka M, Majka S, Cool CD, Fagan KA, Klemm DJ, Hersh LB, Gerard NP, Gerard C, Miller YE.

Am J Pathol. 2009 Mar;174(3):782-96. doi: 10.2353/ajpath.2009.080345.

31.

Detection and localization of intraepithelial neoplasia and invasive carcinoma using fluorescence-reflectance bronchoscopy: an international, multicenter clinical trial.

Edell E, Lam S, Pass H, Miller YE, Sutedja T, Kennedy T, Loewen G, Keith RL, Gazdar A.

J Thorac Oncol. 2009 Jan;4(1):49-54. doi: 10.1097/JTO.0b013e3181914506. Erratum in: J Thorac Oncol. 2009 Apr;4(4):558. Gazdar, Adi [added].

32.

Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making.

Erickson TM, Koeppe JR, Miller YE, Stuart RW, Camidge DR.

J Thorac Oncol. 2008 Nov;3(11):1353-5. doi: 10.1097/JTO.0b013e31818b1ae1.

33.

Minimizing unintended consequences of detecting lung nodules by computed tomography.

Miller YE.

Am J Respir Crit Care Med. 2008 Nov 1;178(9):891-2. doi: 10.1164/rccm.200808-1257ED. No abstract available.

PMID:
18945870
34.

Overexpression of Sprouty 2 in mouse lung epithelium inhibits urethane-induced tumorigenesis.

Minowada G, Miller YE.

Am J Respir Cell Mol Biol. 2009 Jan;40(1):31-7. doi: 10.1165/rcmb.2008-0147OC. Epub 2008 Jul 17.

35.

Tumour necrosis factor gene polymorphisms are associated with COPD.

Gingo MR, Silveira LJ, Miller YE, Friedlander AL, Cosgrove GP, Chan ED, Maier LA, Bowler RP.

Eur Respir J. 2008 May;31(5):1005-12. doi: 10.1183/09031936.00100307. Epub 2008 Feb 6.

36.

Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity.

Byers T, Wolf HJ, Franklin WA, Braudrick S, Merrick DT, Shroyer KR, Hirsch FR, Zeng C, Barón AE, Bunn PA, Miller YE, Kennedy TC.

Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):158-62. doi: 10.1158/1055-9965.EPI-07-0436.

37.

Bronchial epithelial Ki-67 index is related to histology, smoking, and gender, but not lung cancer or chronic obstructive pulmonary disease.

Miller YE, Blatchford P, Hyun DS, Keith RL, Kennedy TC, Wolf H, Byers T, Bunn PA Jr, Lewis MT, Franklin WA, Hirsch FR, Kittelson J.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2425-31.

38.

Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer.

Jonsson S, Varella-Garcia M, Miller YE, Wolf HJ, Byers T, Braudrick S, Kiatsimkul P, Lewis M, Kennedy TC, Keith RL, Bjornsson J, McWilliams A, Lam S, Hirsch FR, Franklin WA.

Am J Respir Crit Care Med. 2008 Feb 1;177(3):342-7. Epub 2007 Nov 7.

39.

Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer.

Varella-Garcia M, Chen L, Powell RL, Hirsch FR, Kennedy TC, Keith R, Miller YE, Mitchell JD, Franklin WA.

Am J Respir Crit Care Med. 2007 Sep 1;176(5):505-12. Epub 2007 Jun 28.

40.

Lack of association between sputum atypia and chronic obstructive pulmonary disease mortality.

Miller YE, Vu KO, Kennedy TC, Hirsch FR, Petty TL, Bunn PA Jr, Keith RL, Franklin WA, Wolf HJ, Prindiville S, Byers T.

J Thorac Oncol. 2006 May;1(4):302-7.

41.

Inhaled corticosteroids and lung cancer chemoprevention.

Miller YE, Keith RL.

Am J Respir Crit Care Med. 2007 Apr 1;175(7):636-7. No abstract available.

PMID:
17384324
42.

Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer.

Merrick DT, Kittelson J, Winterhalder R, Kotantoulas G, Ingeberg S, Keith RL, Kennedy TC, Miller YE, Franklin WA, Hirsch FR.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2281-8.

43.

Stridor in a 47-year-old man with inflammatory bowel disease.

Janssen WJ, Bierig LN, Beuther DA, Miller YE.

Chest. 2006 Apr;129(4):1100-6. No abstract available.

PMID:
16608963
44.

Update in lung cancer 2005.

Jett JR, Miller YE.

Am J Respir Crit Care Med. 2006 Apr 1;173(7):695-7. Review. No abstract available.

PMID:
16556699
45.

Role of rho in the increased migration of pulmonary artery smooth muscle cells observed in the neprilysin knockout mouse.

Karoor V, Walchak SJ, Miller YE, Dempsey EC.

Chest. 2005 Dec;128(6 Suppl):582S-583S. No abstract available.

PMID:
16373846
46.

Proteomic patterns of preinvasive bronchial lesions.

Rahman SM, Shyr Y, Yildiz PB, Gonzalez AL, Li H, Zhang X, Chaurand P, Yanagisawa K, Slovis BS, Miller RF, Ninan M, Miller YE, Franklin WA, Caprioli RM, Carbone DP, Massion PP.

Am J Respir Crit Care Med. 2005 Dec 15;172(12):1556-62. Epub 2005 Sep 22.

47.

Pathogenesis of lung cancer: 100 year report.

Miller YE.

Am J Respir Cell Mol Biol. 2005 Sep;33(3):216-23. Review.

48.

Genetic susceptibility to lung cancer.

Miller YE, Fain P.

Semin Respir Crit Care Med. 2003 Apr;24(2):197-204.

PMID:
16088539
49.

High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia.

Kennedy TC, Franklin WA, Prindiville SA, Cook R, Dempsey EC, Keith RL, Hirsch FR, Merrick TA, Shroyer KR, Petty TL, Byers T, Bunn PA Jr, Miller YE.

Lung Cancer. 2005 Aug;49(2):187-91. Epub 2005 Apr 14.

PMID:
16022912
50.

Lung cancer: genetics of risk and advances in chemoprevention.

Keith RL, Miller YE.

Curr Opin Pulm Med. 2005 Jul;11(4):265-71. Review.

PMID:
15928489

Supplemental Content

Loading ...
Support Center